Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 3
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatm…
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2+ Breast Cancer
Estimated
~$10 – $6,250
Alliance for Clinical Trials in OncologyNCT06876714
Phase 1
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with…
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
Estimated
~$10 – $8,750
Phase 2
A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo…
Breast CancerPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Estimated
~$10 – $8,750
Criterium, Inc.NCT05458674
Phase 2
Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an eff…
Oligometastatic Breast CarcinomaBreast CancerMetastatic Breast Cancer+3 more
Estimated
~$10 – $6,250
Memorial Sloan Kettering Cancer CenterNCT05534438